





AFRICAN JOURNAL OF CLINICAL AND EXPERIMENTAL MICROBIOLOGY       JANUARY2012             ISBN 1595-689X    VOL 13(1) 
AJCEM/201176/21202                              -http://www.ajol.info/journals/ajcem 
COPYRIGHT 2012 
AFR. J. CLN. EXPER. MICROBIOL 13(1): 56-60 http://dx.doi.org/10.4314/ajcem/v13i1.7 
 
ASSESSMENT OF THE DIAGNOSTIC POTENTIAL OF CLINOTECH TB SCREEN TEST 
FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS IN NIGERIA 
 
EKUNDAYO1 , E. O.,  ABBEY2, S.D. AND ACHI1, O.K. 
1 Department of Microbiology, College of Natural and Applied Sciences, Michael Okpara University of Agriculture, Umudike, 
Abia State. 2 Department of Medical Laboratory Science, Faculty of Science, Rivers State University of Science and Technology, 
Nkpolu, Port Harcourt 
 
Correspondence to: E. O. Ekundayo (emma_ekundayo@yahoo.com). 
ABSTRACT 
The Clinotech TB Screen test,  a 3rd generation multi-antigen rapid chromatographic immunoassay for detection of IgG 
antibodies in serum against recombinant protein antigens 38kDa, 16kDa and 6kDa, was  assessed for its  diagnostic potential for 
diagnosis of active pulmonary TB in routine TB control programme in Abia State, Nigeria. The overall sensitivity and 
specificity of Clinotech TB Screen test were 24.1% and 87.8% (95% Confidence intervals [CI]: 14.7-33.5% and 80.6-95.0%) 
respectively. The positive and Negative Predictive Values (PPV and NPV) were 79.2% and 37.5% respectively. The performance 
of the test was inferior to that of the sputum smear microscopy which had a sensitivity of 50.0% (95% CI, 39.0%-61.0%) and 
specificity of 92.3(95% CI: 86.4-98.2%).  In 37 culture positive smear positive PTB cases, Clinotech TB Screen test was positive in 
18(48.65%). The rapid test showed a very low degree of sensitivity in smear –negative culture positive PTB cases; detecting just 
one (2.38%) out of 42 cases. These results indicate that the diagnostic value of Clinotech TB Screen test for routine diagnosis of 
PTB in this setting is limited. 
 
Key words: Tuberculosis, serological tests, immunochromatographic tests, rapid TB tests 
 
INTRODUCTION 
Diagnosis is a key element in the global plan to 
control TB (1). Rapid and accurate diagnosis is critical 
to effective TB care and interruption of transmission 
(2). However, lack of simple, rapid and accurate 
diagnostic tests remains one of the greatest 
constraints for effective control of TB, especially in 
developing countries where the highest burdens of TB 
are found and facilities for performing traditional 
laboratory diagnosis are inadequate or not available 
(3). Furthermore, the existing conventional diagnostic 
methods such as sputum smear microscopy (SSM), 
culture and chest radiography have technical and 
operational characteristics that limit the quality and 
the scope of their applications in developing countries 
(4).  
Rapid Diagnostic tests (RDTs) employing 
immunological principles to detect antibodies have 
recently been developed. These tests are attractive 
because they are easy to use, rapid, and relatively 
inexpensive and without the need for sophisticated 
laboratory infrastructure (5). They hold out a great 
promise of providing the developing countries with 
an invaluable way to quickly and cheaply diagnose 
infectious diseases (6). 
 
 
Many antigens of Mycobacterium tuberculosis have 
been isolated, purified and tested for their potential 
for development of rapid serological tests (7). Some of 
these antigens have been employed in developing 
commercial serological TB tests (8). Clinotech TB 
Screen from Clinotech Diagnostics and 
Pharmaceuticals, Inc, Canada, is one of such tests 
being distributed in several developing countries 
including Nigeria. Evaluation of several rapid TB 
serological tests showed that the tests have variable 
performance in different epidemiological settings (5). 
We conducted the present study to assess the 
diagnostic performance characteristics of Clinotech 
TB Screen for diagnosis of pulmonary tuberculosis in 
Abia State, Nigeria. 
MATERIALS AND METHODS 
Study Participants.  
The study participants were recruited from TB 
suspects, defined as patients with cough of at least 3 
weeks’ duration referred to the Leprosy and 
Tuberculosis Referral Hospital, Uzuakoli, Bende Local 
Government Area (LGA) and Aba South LGA Health 
Office, Aba, two major directly observed treatment 
short course (DOTS) centres within the Abia State TB 





microscopy investigation for pulmonary tuberculosis 
(PTB) between November 2008 and February 2010.  
Eligible study participants were TB suspects 15 years 
and above who were not on antituberculosis 
treatment at the time of recruitment. The study 
included 150 TB suspects who met the inclusion 
criteria and were prospectively enrolled as study 
participants. Informed consent for participation was 
obtained from the study participants. The study 
protocol was approved by the Ethical Committee of 
the Federal Medical Centre (FMC), Umuahia, Abia 
State.  
Three sputum samples, one spot sample on the first 
day of patient visit, an early morning sample brought 
from home the next day, and the second spot sample 
collected when the patient brought the early morning 
specimen, were obtained from each study participant. 
Venous blood samples were also collected from the 
TB suspects for serological TB tests. The blood 
samples were collected into anticoagulant free plastic 
tubes from which the sera were later separated.  
Sputum smear microscopy and sputum culture 
For sputum smear microscopy, direct sputum smears 
were made from the sputum samples and stained by 
the Ziehl-Neelsen staining technique for acid-fast 
bacilli (AFB). For culture, the sputum samples were 
decontaminated using modified Petroff”s alkali 
method and concentrated by centrifugation at 
3,000rpm for 30 minutes. The processed sputum 
samples were cultured on Lowenstein-Jensen (LJ) 
medium and incubated at 37oC and examined for 
growth daily for the first 7 days and twice weekly 
thereafter up to 8th week until a definite result was 
obtained. The slants that did not showed any growth 
after 8 weeks of incubation were recorded as culture 
negative.  
Clinotech TB Screen test  
The Clinotech TB Screen test was manufactured by 
Clinotech Diagnostics and Pharmaceuticals, Inc, 
Canada and distributed in Nigeria by Clinotech 
Nigeria Limited, Lagos. The Clinotech TB Screen test 
is a 3rd generation chromatographic immunoassay 
(CIA) using direct binding double sandwich antibody 
(Ab-Ag-Ab) principle for direct qualitative detection 
of TB antibody in human serum or plasma. The test is 
a multi-antigen test containing recombinant M. 
tuberculosis antigens 38kDa, 16kDa and 6kDa 
conjugated to colloidal gold particles and 
immobilized on the test membrane.  
The test was done according to the manufacturer’s 
instructions contained in the package insert. The test 
device was removed from the pouch and placed on a 
clean, dry level surface. Using the plastic pipette 
provided in the test pouch, serum was drawn up to 
the 100µl mark on the pipette and applied into the 
sample application well. The test result was read at 15 
minutes after sample application and interpreted 




Clinotech TB Screen test was compared with sputum 
smear microscopy in 150 TB suspects. The sputum 
samples of 52(37.14%) of the patients were positive 
for AFB. Clinotech TB Screen test was positive in 26 
(50.00%) of the 52 smear positive cases and 6 (6.12%) 
of the 98 smear negative cases. In total the Clinotech 
TB Screen was positive for anti-TB antibodies in 32 
(22.86%) of the total study participants. The ability of 
the test to detect the smear-positive cases according to 
AFB grading is shown in Table 1. The ability of the 
Clinotech TB Screen test to identify the culture 
positive PTB cases is shown in Table 2. In 37 culture 
and smear positive PTB cases, the test was positive in 
18 (48.65%) and in 1 (2.38%) of 42 culture-positive but 
smear-negative PTB cases. 
 
TABLE 1: PERFORMANCE OF CLINOTECH  
TB SCREEN TEST IN SPUTUM SMEAR  









































   
TOTAL 52 (100) 26/52 (50.00) 
 
 a 1-9 AFB/100HPF (high power field) 
 b 10-99 AFB/100HPF 
 c 1-10 AFB/HPF 
 d >10AFB/HPF 
 SSM- Sputum smear microscopy 
 
The overall performance of the test against a reference 
standard of sputum culture is presented in Table 3. 
The sensitivity and specificity were 24.1% and 87.8% 





values were 79.2% and 37.5% respectively. The 
combination of the results of Clinotech TB Screen test 
with those of smear microscopy resulted in the  
improvement of the sensitivity from 24.1% to 51.4% 
but with a corresponding decrease of specificity from 
87.8% to 80.9%.  
 
 
TABLE 2: DETECTION OF CULTURE POSITIVE PTB CASES BY CLINOTECH TB SCREEN TEST 
 
 
Diagnostic category No. of 
cases 
  No.  Positive (% )         No. Negative (%) No. (%) with 
low signal 
result (Faint) 
     
Culture positive, smear 









    1 (5.55) 
Culture positive, smear 








     
    0 (0) 
Culture positive, smear 
positive (*NTM) 
8 3 (37.50) 5 (62.25)     0 (0) 
 













    0 (0) 
 
*NTM - Nontuberculous mycobacteria  
 
TABLE 3. SENSITIVITY, SPECIFICITY, PPV AND NPV OF CLINOTECH 
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a95% CI- 95% Confidence Interval 
PPV-    Positive Predictive value 
NPV-   Negative Predictive Value 
 
DISCUSSION 
We have assessed the diagnostic potential of 
Clinotech TB Screen test for diagnosis of active 
pulmonary TB in routine TB control programme in 
Abia State, Nigeria. The performance of the test was  
 
inferior to that of the sputum smear microscopy. 
While the sputum smear microscopy had a sensitivity 
of 50.0% (95% Confidence interval [CI], 39.0%-61.0%), 





(95% CI: 14.7%-33.5%). In 37 culture positive smear 
positive PTB cases, Clinotech was positive only in 
18(48.65%). The rapid test showed a very low degree 
of sensitivity (2%), detecting just one of 42 cases of 
smear –negative culture positive PTB cases in this 
study. The overall sensitivity and specificity of 
Clinotech TB Screen test were 24.1% and 87.8% (95% 
CI: 80.6-95.0%) respectively. The positive and 
Negative Predictive Values (PPV and NPV) were 
79.2% and 37.5% respectively. These values indicate 
that the diagnostic value of Clinotech TB Screen test 
for routine diagnosis of PTB in this setting is limited. 
Previous evaluations of serological TB tests in Nigeria 
showed variable performance of low to moderate 
sensitivities.  The ELISA-based Pathozyme TB EIA 
kits (Pathozyme-TB Complex Plus, Pathozyme Myco 
A, Myco M and Myco G were evaluated in Lagos by 
Enwuru et al. (9). These kits employed 38kDa and 
16kDa antigens as in Clinotech TB Screen test.  The 
authors reported sensitivities of 4% for Myco A, 24% 
for Myco M and 76% for Myco G with specificity of 
100% for Myco G in smear and culture positive 
category. The performance of Clinotech TB Screen test   
in our study appeared to be lower than that of Myco 
G which is the kit in that series that was directed at 
detecting IgG antibodies. Ohanu et al. (10) reported 
the evaluation of the SmartCheck TB 
immunochromatographic test in a hospital-based 
study in Enugu, Nigeria. They used sputum smear 
microscopy as reference standard and compared the 
test with X-ray. The sensitivity was reported as 89.5% 
and the specificity was 77.7%. It is difficult to make a 
direct comparison of our results with this study 
because we used culture as reference standard and 
because the identity of mycobacterial antigen used in 
the SmartCheck TB was not stated in the paper.  Our 
results are similar to those of Kassa-Kelembho et al. 
(11) who reported a sensitivity of 20.6% and 
specificity of 90.3% for SDHO MTB test in Bangui, 
Central African Republic. 
Poor diagnostic performance of rapid TB tests has 
been reported in several previous studies. In a study 
conducted by Pottumarthy et al. (12) to compare the 
accuracy of seven antibody detection tests for 
diagnosis of tuberculosis in New Zealand among 
immigrants from countries with a high prevalence of 
tuberculosis, the sensitivity ranged from 16% to 57%. 
The two immunochromatographic tests, ICT 
Tuberculosis and Rapid Test TB, included in that 
study had sensitivity of 41% and 25% respectively. 
The corresponding specificities were 96% and 87% 
respectively. The results of laboratory –based 
evaluation of 19 commercially available rapid 
diagnostic tests for TB sponsored by Special 
Programme for Research and Training in Tropical 
Diseases (TDR)  between 2005 and 2006 showed that 
the sensitivity of the tests ranged from 0.97% to 
59.7%; specificity ranged from 53% to 98.7% (13). 
Clinotech TB Screen test was not included in the TDR 
study because the manufacturer declined to 
participate in the study.  The evaluation of this test is 
reported for the first time in this study. Anderson et 
al. (14) evaluated three ELISA based TB antibody 
tests, InBios Active Tb Detect, IBL M. tuberculosis and 
Anda Biologics TB which utilized newer 
mycobacterial antigens: Mtb81, Mtb8, Mtb48, DPEP 
(MPT32) in addition to 38-KDa protein, and two 
additional proprietary antigens.  The sensitivity of 
InBios Active Tb Detect was 83.3%, IBL M. tuberculosis 
had sensitivity of 5.6% and Anda Biologics TB had 
83.3% with corresponding specificities of 98.9%, 100% 
and 72% respectively.  
Although we found the Clinotech TB Screen test to be 
a rapid and easy to use test, the low sensitivity of the 
test makes it unsuitable for use as a stand alone test 
for routine diagnosis of TB in this setting.  
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